Skip to main content
European Respiratory Review logoLink to European Respiratory Review
. 2025 Nov 5;34(178):250038. doi: 10.1183/16000617.0038-2025

A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria

Charles L Daley 1,2,✉, Patrick A Flume 3, Jakko van Ingen 4, Reeti Khare 1,5, Christina M Mingora 3, Minh-Vu H Nguyen 6, Kevin L Winthrop 7,8, B Shoshana Zha 9,10
PMCID: PMC12588081  PMID: 41193247

Abstract

Background

The incidence and prevalence of disease caused by nontuberculous mycobacteria (NTM) are increasing globally, yet treatment regimens remain complex and often ineffective. Newer tetracyclines have shown promise as a potent therapeutic. In this systematic review, we assessed the evidence for the use of tetracyclines for the treatment of NTM disease, complemented by a narrative review of nonclinical data.

Methods

Medline (PubMed) and Web of Science were searched from inception to February 2024 for clinical studies that assessed the safety, tolerability or efficacy of tetracyclines for NTM disease. Search results were screened against pre-defined inclusion and exclusion criteria. Nonclinical data were identified using a targeted literature search and are presented in a narrative synthesis.

Results

A total of 89 citations were included, comprising 43 clinical studies (six prospective observational studies, 18 retrospective studies and 19 case series) and 46 nonclinical studies. Nonclinical studies demonstrated potent in vitro activity for tigecycline, omadacycline and eravacycline, particularly against rapidly growing mycobacteria (RGM). No randomised controlled trials (RCTs) were identified. Most clinical experience was for RGM (largely Mycobacterium abscessus) and supported the use of newer tetracyclines. Evidence for the treatment of slowly growing mycobacteria, particularly Mycobacterium avium complex, was more limited.

Conclusions

There remains a significant unmet need for effective, well-tolerated therapies for the treatment of NTM, especially those that improve quality of life. Although tetracyclines have not been evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease and further RCTs are warranted.

Shareable abstract

New and effective antimicrobial treatments for NTM disease are urgently needed. Although not yet evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease. https://bit.ly/4oIZ42u

Introduction

Nontuberculous mycobacteria (NTM) encompass over 190 species (excluding Mycobacterium tuberculosis complex and M. leprae) and are divided into rapidly (RGM) and slowly (SGM) growing mycobacteria. While the majority of NTM are not pathogenic, a subset of species can cause disease in humans [1], especially in individuals with underlying structural lung disease and/or immunodeficiencies [1, 2]. The most common clinically pathogenic NTM are the slowly growing M. avium complex (MAC) and M. kansasii, and the rapidly growing M. abscessus [1].

Although specific antibiotic regimens have been established, treatment outcomes remain suboptimal for most NTM species with low rates of cure [2, 3]. The majority of antibiotics used in the treatment of NTM have been borrowed from Mycobacterium tuberculosis treatment regimens, which are nonspecific and often ineffective. Indeed, there is only one approved antibiotic for NTM pulmonary disease, amikacin liposome inhalation suspension, which is approved by multiple regulatory committees for the treatment of refractory MAC pulmonary disease [3–6]. Azithromycin and clarithromycin, both macrolides, are approved by the US Food and Drug Administration for the treatment of disseminated MAC disease in patients with advanced HIV [7, 8], but not specifically for other disease states. Further, current guideline regimens are associated with significant side-effects and complications, reducing adherence and leaving much to be desired [9, 10].

Past and current NTM guidelines have included tetracycline antibiotics (doxycycline, minocycline and tigecycline) as potential treatment options for M. abscessus [3, 11–14]. Tetracyclines inhibit bacterial protein synthesis, through binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome. Whilst tetracyclines exhibit broad-spectrum activity, bacteria, including NTM, have developed resistance mechanisms. Consequently, many RGM species are frequently resistant to doxycycline and minocycline in vitro, limiting these as a viable option and explaining their exclusion from current NTM guidelines [15–19]. Tigecycline, omadacycline and eravacycline have demonstrated more potent in vitro activity against M. abscessus and several other RGM species than doxycycline and minocycline [20, 21]. This systematic literature review seeks to assess the efficacy of tetracyclines for the treatment of NTM through nonclinical and clinical data, potentially providing an improved option in regimen enhancement.

Methodology

This review aimed to identify relevant evidence regarding the efficacy and safety of tetracyclines for the treatment of pulmonary and extrapulmonary NTM disease. Clinical evidence was identified through a systematic analysis of the literature and supporting nonclinical data was identified through a targeted literature search. Detailed methodology can be found in the supplementary materials.

Clinical systematic review methodology

This review is registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024540059) and was designed and conducted in line with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Systematic searches were performed in February 2024 in Medline (PubMed) (supplementary table S1) and Web of Science (WoS) (supplementary table S2). Abstracts from key congresses were identified through the congress website or from WoS. Results were deduplicated, then screened by title and abstract using an automated method and were checked by two reviewers (Bioscript Group (Macclesfield, UK) and Daniel Deck (Paratek Pharmaceuticals, Inc)). Full-text review and data extraction were also carried out using an automated method and results were checked by the same two reviewers, and the results reviewed and approved by all authors. Level and quality of evidence for use of tetracyclines against NTM species was assessed using grading systems and outlined in the supplementary material [22, 23]. A traffic light system was also used to grade the strength of evidence in favour of each tetracycline for each NTM species.

Methodology for review of nonclinical data

Nonclinical data were identified using a targeted literature search, with studies selected and agreed upon by all authors to support the clinical systematic review and explain key properties of tetracyclines against clinically relevant NTM species.

Results

Included studies

A total of 1382 citations (nonclinical and clinical) were identified; automated duplicate screening removed 328 of these (figure 1). Automated keyword screening of the title, abstract and MeSH (Medical Subject Headings) terms was performed on the remaining 1054 references, which removed a further 702 references. One systematic review and three meta-analyses were identified, and the bibliographies of these were assessed for relevant grey literature sources. 31 references were included as grey literature. All studies (n=383) were split into three pools of data, as follows: nonclinical (n=141), clinical (including case series involving ≥3 cases; n=81) and case reports (involving <3 cases; n=161). Case reports were excluded due to their diverse nature. The clinical studies underwent a second manual screening and 24 of those references were excluded against the pre-defined exclusion and inclusion criteria (supplementary table S3).

FIGURE 1.

FIGURE 1

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram. ATS: American Thoracic Society; ID: infectious diseases. #: Congress abstracts were identified through congress website searches for 2021 and 2022, and Web of Science for 2023. : 137 nonclinical studies were identified in this search; a targeted review of these and additional nonclinical studies suggested by the author group was carried out for inclusion to support the clinical section of this paper. +: Clinical data included case series (≥3 cases).§: Case reports and case series (<3 cases) were excluded.

Of the clinical studies, 57 underwent data extraction to confirm the reporting of relevant data and 43 clinical studies were included in the review. Nonclinical data were excluded from the systematic literature review and relevant studies were selected through a targeted review of the 141 identified nonclinical studies. A total of 46 nonclinical studies were agreed upon by all authors and were included in the review. Nonclinical studies were included if they reported relevant in vitro or in vivo data (minimum inhibitory concentration (MIC) studies, time-kill studies, hollow-fibre model (HFM), human macrophage models and animal studies).

Nonclinical review of tetracyclines for NTM

Rapidly growing nontuberculous mycobacteria evidence

Studies assessing the in vitro activity of tetracycline antibiotics against RGM species via broth microdilution are reported in table 1 and supplementary tables S5–S7 [18, 24–31]. Doxycycline, minocycline and sarecycline demonstrated poor in vitro activity against the RGM species tested [18, 24–27, 30, 31]. In contrast, tigecycline demonstrated potent in vitro activity against RGM across multiple studies including a recent large US surveillance study (table 1).

TABLE 1.

In vitro activity of tetracycline antibiotics against Mycobacterium abscessus

First author [ref.], year (country) Subspecies n Incubation
temperature (°C)/time (days)
MIC50/MIC90 (µg·mL−1)#
DOX MIN TIG OMC ERV SAR
Shoen [24] 2019 (USA) NS 24 37/5 >64/>64 – 1/2 1/2 – –
Kaushik [28] 2019 (USA)+ M. abscessus 16 30/3 – – 1/2 2/4 0.5/2 –
M. massiliense + M. bolletii 12 – – 1/2 1/2 0.25/0.5 –
Brown-Elliott [25] 2021 (USA)§ M. abscessus 20 30/3 >8/>8 >8/>8 0.12/0.25 0.12/0.25 – –
M. massiliense 3 >8/– >8/– 0.25 0.12 – –
Chew [26] 2021 (Singapore) NS 211 30/3–5 >16/>16 >8/>8 0.5/1 – 0.12/0.25 –
Brown-Elliott [27] 2022 (USA)§ M. abscessus 8 30/3–4 >16/>16 >8/>8 0.12/0.25 – 0.12/0.5 –
M. massiliense 5 >16/>16 >8/>8 0.25/0.25 – 0.12/0.5 –
Nicklas [29] 2022 (USA) M. abscessus 12 30/3 – – 0.125/0.25 0.25/0.5 – –
M. massiliense 9 – – 0.125/0.5 0.25/1.0 – –
NS 10 – – 0.125/0.25 0.125/0.5 – –
Zhang [30] 2022 (China)+ M. abscessus 44 37/3 – – 0.5/1 0.5/1 0.125/0.25 >8/>8
M. massiliense 29 – – 0.5/1 1/2 0.125/0.25 >8/>8
Li [31] 2023 (China)+ M. abscessus 147 30/3 – – 0.5/2 1/4 1/4 >8/>8
M. massiliense 46 – – 1/2 2/4 1/4 >8/>8
M. abscessus 23 37/3 – – 0.5/2 2/4 0.5/4 >8/>8
M. massiliense 6 – – 1/8 2/8 1/8 >8/>8
Hunkins [18] 2023 (USA) M. abscessus 1344 30–32/3–5 >16/>16 >8/>8 1/2 – – –
M. bolletii 93 >16/>16 >8/>8 1/2 – – –
M. massiliense 754 >16/>16 >8/>8 1/2 – – –

–: Not reported. DOX: doxycycline; ERV: eravacycline; MIC: minimum inhibitory concentration; MIN: minocycline; NS: subspecies not specified; OMC: omadacycline; SAR: sarecycline; TIG: tigecycline. #: MIC inhibiting 50% (MIC50) and 90% of isolates (MIC90) and values are as reported in the cited references. If values for subspecies were not reported these were calculated from the data provided, if available. : n=14 for tigecycline. +: The omadacycline powder used in these studies failed to meet equivalence and results should be interpreted with caution [119]. §: Both 80% and 100% inhibition values were reported in the studies by Brown-Elliott et al. [25, 27]; only 100% inhibition MIC values are reported here.

Omadacycline and eravacycline also demonstrated potent in vitro activity against all RGM species tested [18, 24–31], with MIC inhibiting 50% (MIC50) and 90% of isolates (MIC90) values generally within two dilutions of the reported tigecycline MICs for M. abscessus (table 1). The in vitro activity of tigecycline, omadacycline or eravacycline in combination with another antibiotic against M. abscessus has also been evaluated using a checkerboard microbroth dilution technique (supplementary table S7) [29, 32–39]. No antagonism was reported with any combination, which is important as combination therapy is recommended for NTM treatment [3]. Consistent with their in vitro activity versus M. abscessus, tigecycline and omadacycline show promising activity in time-kill [29, 40–45], HFM [46, 47], intracellular [42, 48, 49] and animal models [29, 33, 42, 50–52]. Based upon these in vitro data, omadacycline, eravacycline and tigecycline are treatment candidates for infections caused by RGM species, most notably M. abscessus, whilst doxycycline and minocycline are expected to have a limited role due to the high MIC values reported in most species.

Slowly growing nontuberculous mycobacteria evidence

The in vitro activity of tetracycline antibiotics against SGM, including MAC and M. kansasii, has been evaluated in broth microdilution studies [21, 25, 27, 53], time-kill studies [54, 55] and the HFM [54, 56–60]. Both doxycycline and minocycline demonstrated poor in vitro activity against most SGM species tested, including MAC and M. kansasii, and modest, and activity was observed for doxycycline and minocycline against M. marinum [53]. MIC50 values for tigecycline, omadacycline and eravacycline for MAC and M. kansasii were ≥8 mg·L−1 for all three compounds [21, 25, 27]. These MIC values for SGM must be interpreted with caution. Drug instability within the tetracycline class and its impact on antibiotic susceptibility testing of NTM is well recognised [61–63]. Drug degradation during the extended incubation period required for SGM may compromise the accuracy of broth microdilution assays, leading to an underestimation of the in vitro potency of these agents [61].

Time-kill and HFM studies can overcome issues related to drug instability through supplementation to replace degraded drug or the use of freshly prepared drug for each dose, respectively. In time-kill studies, minocycline and tigecycline both demonstrated activity against MAC [54, 55]. Minocycline, tigecycline and omadacycline have also demonstrated potential activity against M. avium in HFMs [54, 56, 57, 59, 64, 65]; however, additional studies are needed to identify the most potent and durable combinations. In an HFM of M. kansasii infection, both minocycline and omadacycline showed potent activity when part of a regimen, in comparison to guideline-recommended regimens [58, 60], suggesting that minocycline and omadacycline-based regimens warrant further study.

Systematic clinical review of use of tetracyclines in NTM disease

Rapidly growing nontuberculous mycobacteria clinical evidence

28 clinical studies or case series reported on use of tetracyclines for treatment of disease caused by RGM (supplementary table S8). Of these, four were prospective observational studies, 11 were retrospective studies and 13 were case series [66–78]. Some studies reported on data for multiple organisms; however, the most common causative pathogen reported across all studies was M. abscessus (n=23 studies) with fewer studies reporting data for M. chelonae (n=7 studies) and M. fortuitum (n=6 studies). In a small number of studies, the causative organism was not clearly identified.

M. abscessus: retrospective studies

For pulmonary disease caused by M. abscessus, three studies utilised a tetracycline-containing combination regimen of doxycycline, a macrolide and a fluoroquinolone, along with an initial 4-week intravenous course of cefoxitin (or imipenem) and amikacin [79–81]. Treatment with this combination regimen resulted in sputum conversion and maintenance of negative sputum cultures for >12 months in 38/65 (58%) patients. However, none of the isolates were susceptible to doxycycline and sputum culture conversion was only associated with macrolide susceptibility [81]. A follow-up study that analysed outcomes by subspecies demonstrated that sputum culture conversion and maintenance of negative cultures was higher in patients with M. abscessus subsp. massiliense infection than in those with subsp. abscessus infection (88% versus 25%, respectively; p<0.001) [80]. A further study reported on treatment outcomes for patients with M. abscessus subsp. abscessus disease who received doxycycline (17/67 (35%)). In these 17 patients, a similar percentage experienced favourable and unfavourable treatment responses (21% versus 28% respectively, p=0.53). The investigators noted high rates of doxycycline resistance in vitro, leading to its exclusion from the treatment protocol midway through the study [79].

Seven studies investigated the use of tigecycline-containing regimens in the treatment of M. abscessus pulmonary disease [82–88] (table 2). Two studies found that treatment with tigecycline-containing regimens was associated with higher rates of clinical success compared to other antibiotics. In a single-centre analysis of 244 patients, drug combinations including tigecycline were associated with clinical success (adjusted odds ratio (aOR) 2.04, 95% CI 1.08–3.86; p=0.028) while doxycycline (p=0.229) or minocycline (p=0.986) were not [82]. Similarly, a multicentre analysis of 71 patients demonstrated improved microbiologic conversion (aOR 17.72, 95% CI 1.23–267.21; p=0.03) and treatment success (aOR 14.09, 95% CI 1.10–166.67; p=0.04) with treatment regimens containing tigecycline plus amikacin compared with amikacin-based regimens that did not include tigecycline or other regimens containing a macrolide, imipenem and fluoroquinolone [85].

TABLE 2.

Clinical studies with tigecycline and omadacycline in the treatment of Mycobacterium abscessus disease

First author [ref.], year Number of patients Tetracycline dose and duration Site of infection Common concomitant antibiotics Treatment outcomes AEs
Tigecycline
 Wallace [88] 2014# 52 total
All treated with TIG
TIG dose ranged from 25 to 100  mg·day−1
Median duration of TIG treatment was 85 days
Lung (69%)
Other (31%)
Macrolides (73%)
Aminoglycosides (56%)
i.v. beta-lactams (37%)
62% (16/26) of patients with PD who received ≥1 month of TIG were clinically improved Nausea (63%)
Vomiting (35%)
AEs leading to TIG discontinuation in 31%
 Czaja [87] 2016 47 total
Five treated with TIG
TIG dose not reported
Mean duration of TIG treatment was ∼3 months
Lung (100%) Not reported for subset treated with TIG TIG use was not associated with an improvement in patient-reported outcome scores ≥MCID at 12 months (OR 0.4, 95% CI 0.1–2.7) Any TIG-related AE in 80%
 Chen [82] 2019 244 total
53 treated with TIG
TIG dose and duration not reported Lung (100%) Not reported for subset treated with TIG TIG use was associated with treatment success (OR 2.04, 95% CI 1.08–3.86; p=0.028)
Treatment success observed in 29% of patients (32/53)
TIG AEs leading to treatment modification in 28% primarily due to nausea and vomiting
 Kwon [86] 2019 35 total
All treated with TIG
Median TIG dose of 50 mg·day−1
Median duration of TIG treatment was 80 days
Lung (83%)
Other (17%)
Amikacin (69%)
Azithromycin (60%)
Imipenem (46%)
Clofazimine (40%)
17% had microbiological improvement
86% had clinical improvement
59% had radiological improvement
TIG discontinuation due to AEs in 46% primarily due to GI AEs including nausea, vomiting and diarrhoea
 Yang [85] 2022 71 total
10 treated with TIG
TIG dose not reported
Mean duration of TIG treatment was 360 days
Lung (100%) All TIG treated patients also received i.v. amikacin TIG and amikacin combination was associated with better microbiological success (aOR 17.7, 95% CI 1.2–267.2; p=0.03) and treatment success (aOR 14.1, 95% CI 1.1–166.7; p=0.04) compared to other regimens Not reported
 Kim [84] 2022 64 total
28 treated with TIG
TIG initial dose was 25 mg·day−1, titrated up to 50  mg·day−1
Median duration of TIG treatment was 28 days
Lung (100%) Amikacin (100%)
i.v. beta-lactam (100%)
Macrolide (100%)
Clofazimine (100%)
Higher rates of negative sputum cultures at 1 month in the TIG group (89%) versus the non-TIG group (50%), p=0.002)
However, short-term use of TIG did not improve the long-term culture conversion rate at 12 months
Not reported
 Im [83] 2023 36 total
27 treated with TIG
TIG initial dose was 25 mg·day−1, titrated up to 50 mg·day−1
Intermittent duration ranging from 2 to 5 weeks
Lung (100%) TIG included in 12 of 14 i.v. regimens; most commonly combined with amikacin and imipenem In patients with disease caused by M. abscessus subsp. abscessus, 62% (16/26) had at least one negative culture result and SCC+ was observed in 12% (3/26) 41% had a TIG dose reduction due to nausea or vomiting
Omadacycline
 Mingora [89] 2023 117 total
All treated with OMC
OMC dose was 300 mg·day−1 in >95% of patients
The median duration of OMC treatment was 8 months
Lung (80%)
Other (20%)
Clofazimine (62%)
Azithromycin (39%)
Inhaled amikacin (35%)
In patients with PD, 46% (44/95) had one or more negative cultures at the time of their final microbiological assessment, with 18% (17/95) achieving culture conversion§ Nausea (21%)
OMC AEs leading to discontinuation in 20%
 El Ghali [90] 2023 # 75 total
All treated with OMC
OMC dose was 300 mg·day−1 in 88% of patients
The median duration of OMC treatment was 6 months
Lung (44%)
Other (56%)
Azithromycin (47%)
Clofazimine (41%)
Oxazolidinone (34%)
Imipenem (31%)
In patients with PD, clinical success and radiological improvement at 3 months was observed in 67% (22/33) and 60% (18/30) of patients, respectively
In those with follow-up sputum cultures, 79% (22/28) achieved culture conversionƒ at a median time of 5 months
GI AEs in 28%
OMC AEs leading to discontinuation in 9%
 Singh [47] 2023 22 total
10 treated with OMC
OMC dose was 300 mg·day−1 in all patients
The median duration of OMC treatment duration was 132 days
Lung (100%) Azithromycin (50%)
Linezolid (40%)
SSCC was achieved in 80% (8/10) versus 11% (1/9), symptom improvement in 100% (8/8) versus 56% (5/9), and therapy discontinuation due to toxicity in 0 versus 33% (3/9) of OMC regimens and comparator regimens, respectively No AEs reported for OMC

AE: adverse effect; aOR: adjusted odds ratio; GI: gastrointestinal; MCID: minimum clinically important difference; OMC: omadacycline; PD: pulmonary disease; SCC: sputum culture conversion; SSCC: sustained sputum culture conversion; TIG: tigecycline. #: M. abscessus made up most cases in the studies by Wallace et al. [88] (73–83%) and El Ghali et al. [90] (80%). All other studies were strictly focused on M. abscessus. : Microbiological improvement was defined as ≥2 consecutive negative sputum cultures. +: SCC was defined as ≥3 consecutive negative sputum cultures after treatment, collected at least 4 weeks apart. §: Culture conversion was defined as two consecutive negative cultures. ƒ: Culture conversion was defined as ≥2 consecutive negative sputum cultures within 12 months of OMC initiation, with no further positive cultures, each taken at least 1 month apart.

Another study evaluated 35 patients treated with tigecycline (median duration of treatment 80.0 days (interquartile range 46.0–179.5 days)) [86]. 29 patients had pulmonary disease and received tigecycline-containing regimens for >1 month; of these, 23 patients were evaluated for microbiological response, with 17% demonstrating ≥2 consecutive negative sputum cultures (defined as microbiological improvement). In contrast to the low rate of microbiological response, the rates of symptomatic and radiological improvements were 86% (25/29) and 59% (16/27), respectively. Despite demonstrating microbial response, studies have demonstrated treatment modification or discontinuation rates of 48–57%, largely due to gastrointestinal adverse events (AEs) that were attributed to tigecycline [85, 86]. Further, a separate study observed significantly higher (p=0.002) rates of culture conversion with short-term tigecycline during a 1-month initial treatment phase (89% (25/28)) compared with regimens without tigecycline (50% (18/36)) [84]. However, rates of culture negativity did not differ significantly between the two groups at 3 months, nor improve long-term culture conversion at 12 months (26% versus 44% for the tigecycline and nontigecycline groups, respectively; p=0.213).

Tigecycline (i.v.) was also evaluated in also evaluating in 26 patients with pulmonary disease caused by M. abscessus subsp. abscessus, who were refractory to antibiotics for >12 months [83]. Of these patients, 62% had at least one negative culture result and culture conversion was observed in three patients. A single patient with M. abscessus subsp. massiliense pulmonary disease treated with tigecycline did not attain any negative cultures. Among patients who received tigecycline, 41% (11/27) had a dose reduction due to nausea or vomiting. Similarly, in a study of tigecycline for salvage treatment, 73.1% of patients had M. abscessus complex infection [88]. Of these 47.4% (18/38) showed improvement following tigecycline treatment, 31.6% (12/38) failed treatment and 21.1% (8/38) had an “indeterminate” response to treatment. However, amongst all patients in this study, the majority (94%) experienced AEs with tigecycline, the most common being nausea (64%) and vomiting (35%). Premature discontinuation of tigecycline occurred in 56% of patients, most often in the first week, before any appreciable antimicrobial effect of the drug and the most common reason for discontinuation was reported as AEs (31%). Furthermore, in a study focused on quality of life in patients with M. abscessus pulmonary disease, tigecycline was not associated with clinically important improvement in the St. George's Respiratory Questionnaire at 12 months (OR 0.4, 95% CI 0.1–2.7), although the number of patients treated with this antibiotic was small (n=5) [87].

Three studies assessed the use of omadacycline for treatment of M. abscessus infection [47, 89, 90]; two included both pulmonary and extrapulmonary cases [89, 90], while the third included only pulmonary disease [47]. The long-term safety of omadacycline was evaluated in patients with M. abscessus disease who received omadacycline as part of a combination regimen for a median duration of 8 months [89]. In patients with pulmonary disease, 46% (44/95) had one or more negative cultures at the time of final microbiological assessment. The most frequently reported AE was nausea (21.4%), with 19.7% of patients stopping treatment due to an AE. Omadacycline treatment was also evaluated in 75 patients with NTM disease [90] with the most common infections being M. abscessus (80%) followed by M. chelonae (12%). The most common sites of infection were lung (44%), skin and soft tissue (25%), and bone (13%). Most patients (93%) received omadacycline as part of a combination regimen (≥2 other antibiotics) with a median duration of 6.2 months (range 3.7–14.6). Among patients with pulmonary disease, the composite clinical success rates at 3, 6 and 12 months were 67%, 70% and 67%, respectively. Of the 28 patients with pulmonary disease who underwent follow-up cultures, 79% achieved culture conversion and the median time to culture conversion was 5 months. Gastrointestinal AEs occurred in 28%, 9.3% patients discontinued omadacycline due to any AE [90]. In an additional retrospective study, outcomes in 22 patients with M. abscessus pulmonary disease were compared with 10 treated with an omadacycline-containing regimen, nine with a tigecycline-containing regimen and three with doxycycline [47]. Sustained sputum culture conversion was achieved in 80% (8/10) of patients in the omadacycline group versus 11% (1/9) in the tigecycline-containing regimen group. No AEs related to omadacycline were reported.

M. abscessus: case series

10 case series reported on outcomes in M. abscessus disease [66–74, 76]. Omadacycline-based regimens were associated with clinical success in 10 of 12 patients with M. abscessus disease across three case series [66, 68, 71]. A single series reported the use of eravacycline for treatment of M. abscessus infection in six solid organ transplant patients [67]. All six patients developed hypofibrinogenaemia prompting discontinuation of eravacycline. Two patients were transitioned to oral omadacycline and fibrinogen levels recovered to baseline and remained stable while receiving omadacycline for durations greater than 30 days. Tigecycline-based combination therapy was associated with positive outcomes in infections caused by M. abscessus and other RGM at various anatomic sites [69, 70, 72, 76]. However, treatment-limiting gastrointestinal AEs were common with tigecycline and led to treatment discontinuation in 49% of patients in one series [76]. Minocycline and doxycycline also showed some success when used as part of a combination regimen for the treatment of M. abscessus infections [73, 74].

M. chelonae: prospective observational studies

Two studies included species specific data for the treatment of M. chelonae infections [88, 91]. In the first, limited species-specific data were available; of the nine patients with M. chelonae infection, five (55.6%) had symptom improvement following tigecycline treatment, three (33.3%) failed treatment and one (11.1%) had an “indeterminant” response to treatment [88]. In the second study, 47 patients were identified as having M. chelonae infections [91]. However, it is important to note that, since the publication of this study in 1985, M. chelonae was reclassified into two different species, M. abscessus and M. chelonae [92, 93]. Approximately two-thirds (68%) of the M. chelonae isolates included in this study would be classified as M. abscessus today and all were resistant to doxycycline. Of the remaining M. chelonae isolates, only 33% (5/15) were susceptible to doxycycline which explains the limited number of patients who received tetracyclines for infections caused by this species.

M. chelonae: case series

Doxycycline and tigecycline demonstrated generally favourable outcomes in a case series evaluating the treatment of M. chelonae infections [75, 78].

M. fortuitum: prospective observational studies

Two studies investigating extrapulmonary disease caused by M. fortuitum infections included doxycycline and minocycline [91, 94]. One study reported the outcomes in 123 patients, of which 76 (63%) had M. fortuitum infections [91]. Doxycycline was used to treat five patients who had localised disease and no systemic symptoms and was also included in the multi-drug regimen of 27% (9/33) of patients who were treated with combination therapy for extensive disease caused by M. fortuitum. Treatment failure occurred in two patients who received doxycycline monotherapy; however, in both cases failure was associated with retained foreign material or a prosthetic device and the bacterial isolate remained susceptible in vitro [91]. The second study reported follow-up for 61 patients with M. fortuitum furunculosis. Of the 48 patients who were treated with antibiotics, 46% received doxycycline and 25% received minocycline. All treated and untreated patients eventually had resolution of disease; however, early administration of antibiotic therapy was associated with shorter duration of disease in persons with multiple lesions [94].

M. fortuitum: case series

Doxycycline and minocycline demonstrated generally favourable outcomes in case series evaluating the treatment infections caused by M. fortuitum [74, 77, 78].

Summary of clinical evidence: RGM

A collated summary of the clinical studies for RGM is provided in table 3. The published clinical studies suggest that doxycycline does not have a clear role in the treatment of M. abscessus pulmonary disease based on high rates of in vitro resistance and poor clinical outcomes. Tigecycline-containing regimens may offer a clinical benefit in patients with M. abscessus infection; however, treatment-limiting AEs are common and the relatively short courses of tigecycline used in some studies did not have a clear impact on long-term culture conversion rates. In the studies evaluating omadacycline, the investigators concluded that the observed clinical or microbiological responses, coupled with the long-term safety and tolerability data, supported further investigation of omadacycline for the treatment of M. abscessus infections. Doxycycline or minocycline may be effective as monotherapy for mild, localised infections caused by susceptible strains of M. fortuitum or M. chelonae. However, the evidence is limited to few studies with a small number of patients and the use of these agents is likely to be limited by the high rates of in vitro resistance reported in these species [14].

TABLE 3.

Summary of clinical evidence for the use of tetracyclines to treat rapidly growing mycobacteria

Species Tetracycline antibiotic Studies (n)/ patients (n)# Efficacy outcomes Safety outcomes Level/quality of evidence
Mycobacterium abscessus DOX [73, 74, 79–82] 6/171
  • Sputum conversion varied: 21–61% [79–81]

  • Treatment efficacy higher (88%) for M. abscessus subsp. massiliense infection than in those with subsp. abscessus infection [80]

  • Lower rates of clinical success observed with DOX compared to TIG (9% and 29%, respectively) [82]

  • Isolate resistance to doxycycline noted in several studies limiting clinical effectiveness [74, 79]

3b; low
TIG [69, 70, 72, 76, 82–88] 11/271
  • Microbiological response (sputum conversion) varied: 12–89% [83, 84, 86]

  • Clinical improvement rates were higher: 47–86% [86, 88]

  • Regimens containing TIG were associated with higher rates of clinical success compared to other antibiotic regimens [82, 85]

  • GI AEs reported across several studies with nausea and vomiting most common [70, 72, 76, 82, 83, 86–88]

  • AEs led to discontinuation/dose reduction in 28–57% of patients [76, 82, 83, 86, 88]

  • TIG-containing treatment regimens did not improve patient QoL [69, 87]

3a; moderate
OMC [47, 66, 68, 71, 89, 90] 6/214
  • Sputum culture conversion varied: 18–80% [47, 89, 90]

  • Clinical success/symptom improvement was high: 67–100% [47, 66, 68, 71, 89, 90]

  • Symptom improvement with OMC was higher than comparator regimens [47]

  • Nausea and GI AEs were observed [66, 89, 90]

  • Discontinuation related to AEs ranged from 9 to 25% [66, 71, 89, 90]

  • Toxicity was lower for OMC compared to comparator regimens [47]

3a; moderate
MIN [73, 74] 2/9 –
  • All isolates were resistant to MIN [74]

4; very low
ERA [67] 1/6 –
  • All six patients developed hypofibrinogenaemia prompting discontinuation of ERA [67]

4; very low
M. chelonae DOX [78, 91] 2/17
  • Only 33% of isolates were susceptible to DOX

  • In two patients, clinical success was 50% [78]

4; very low
TIG [75, 76, 88] 3/18
  • Efficacy of TIG-containing regimens varied: 56–83% [75, 88]

  • AEs reported in >90% of patients+ [88]

  • Common AEs included nausea and vomiting [76, 88]

3b; low
M. fortuitum DOX [74, 77, 78, 91, 94] 5/35
  • Treatment success varied across studies [77, 78, 91, 94] but early antibiotic treatment was associated with faster resolution of infection [94]

  • Successful treatment regimens often included surgery, debridement and multidrug combinations [77, 78]

  • Resistance of some isolates to DOX [74]

3b; low
MIN [74, 94] 2/12
  • Early antibiotic treatment was associated with faster resolution of infection [94]

  • Resistance of some isolates to MIN [74]

3b; very low

The grading systems used for the level and quality of evidence are outlined in the supplementary material. AE: adverse event; DOX: doxycycline; ERA: eravacycline; GI: gastrointestinal; MIN: minocycline; OMC: omadacycline; QoL: quality of life; TIG: tigecycline. #: The total number of patients in the studies who were treated with tetracycline is specified. : Sputum conversion for subspecies abscessus and massiliense reported [80]. +: AEs were reported for the whole study cohort, including both M. abscessus and M. chelonae.

Slowly growing nontuberculous mycobacteria clinical evidence

A total of 15 clinical and case series studies (supplementary table S7) reported on use of tetracyclines for treatment of disease caused by SGM. Two of these were prospective observational studies in MAC pulmonary disease, while seven were retrospective studies and six were case series that reported on skin and soft tissue infections (SSTIs) caused by M. marinum.

M. avium complex: prospective observational studies

Two prospective studies evaluated clarithromycin-based regimens containing minocycline in the treatment of MAC pulmonary disease [95, 96]. In one study involving 45 patients, 31 patients were treated with clarithromycin combinations of which five included minocycline [96]. Overall, 71% of patients had negative sputum cultures after 12 months of treatment although efficacy data for the subset of patients receiving minocycline-containing regimens was not reported. Five patients (11%) developed clarithromycin resistance, including one patient who received the dual combination of clarithromycin plus minocycline. Another study assessed the efficacy and tolerability of clarithromycin in combination with minocycline and clofazimine for 15 months [95]. Among 22 evaluable patients, 64% had persistently negative cultures after ≥6 months' treatment and 59% experienced at least one AE and two patients discontinued treatment due to a severe AE.

M. marinum: retrospective studies

Seven retrospective studies focused on M. marinum SSTIs [97–103]. SSTIs were most often located on the upper extremities and were commonly related to aquatic exposures. Lymphatic spread was relatively common, while joint involvement was present in a small number of cases. A total of 83 patients were treated with tetracyclines, usually as monotherapy.

Four studies reported generally favourable clinical outcomes with tetracycline treatment for M. marinum SSTIs [100–103]. In one study, tetracycline monotherapy was effective in 7/9 (78%) cases; however, success with deeper infections (five tenosynovitis, one septic arthritis) was difficult to determine because either the therapy was changed or relapse occurred after completion of apparently successful therapy [103]. Another study found that minocycline monotherapy was effective in 10/14 (71%) cases compared with 5/5 (100%) cases treated with rifampin plus ethambutol [102]. Minocycline failure may have been related to gastrointestinal AEs leading to treatment discontinuation in two patients. In a study of 38 SSTI cases, the eight patients treated with minocycline (three monotherapy, five with trimethoprim–sulfamethoxazole) showed clinical improvement [101]. Lastly, a survey of M. marinum infections found that minocycline was used in 12 cases, making it the most frequently prescribed antibiotic. Minocycline was associated with positive clinical results and a low incidence of side-effects. Resistance to minocycline was only reported in one case [100].

Three of the studies reported mixed or unfavourable clinical outcomes with tetracycline treatment for M. marinum SSTIs [97–99]. In 27 patients with M. marinum infections, eight patients with fish tank granulomas received doxycycline alone or in combination [99]. Of these, 38% achieved clinical resolution, two received additional surgical debridement and another received additional antibiotic therapy. Only 1/30 M. marinum isolates tested was confirmed to be susceptible to doxycycline. In a recent study involving 40 patients, 10 (25%) were initially treated with doxycycline (n=10) or minocycline (n=4) monotherapy [97]. The wild-type MIC distribution included the breakpoint concentration; in vitro resistance to doxycycline (MIC ≥8 µg·mL−1) was reported in 36% of M. marinum isolates tested, which correlated with poor response to treatment [97]. Seven patients switched from doxycycline/minocycline monotherapy to combination regimens, five due to lack of response and two based on the results of susceptibility testing (measured using broth microdilution according to Clinical and Laboratory Standards Institute guidelines) [104]. One patient was successfully treated with doxycycline despite the isolate demonstrating in vitro resistance [97]. Lastly, a third study found that 6/18 (33%) patients with cutaneous infection were initially treated with minocycline (n=1) or doxycycline (n=5) monotherapy, of which four had treatment terminated due to non-efficacy, relapse or side effects, while the fifth patient was lost to follow-up [98].

M. marinum: case series

Six case series described the use of oral tetracyclines, primarily minocycline, for the treatment of SSTIs caused by M. marinum for a total of 75 patients [105–110]. Five of the six case series reported favourable clinical outcomes with the use of tetracyclines, including the largest case series where treatment success was noted in 94% of patients receiving either minocycline or doxycycline [105–110]. One case series described four patients who did not respond to treatment with a tetracycline after 2–6 weeks [110]. Factors that may have contributed to tetracycline treatment failure included suboptimal dosing, a short duration of treatment and in vitro resistance.

Summary of clinical evidence: SGM

A collated summary of the clinical studies for SGM is provided in table 4. Considering the limited and inconclusive clinical data, minocycline is not a guideline-recommended treatment option for MAC pulmonary disease [3]. Additional clinical studies are needed to determine if minocycline or other tetracyclines have any role in the treatment of MAC pulmonary disease. In contrast, the published retrospective studies and case series support the use of doxycycline and minocycline in the treatment of SSTIs caused by susceptible M. marinum isolates. Resistance to these agents is common and treatment decisions should be guided by the results of susceptibility tests. Monotherapy may be appropriate in superficial skin infections. For the treatment of deeper or more extensive infection, combination therapy should be strongly considered.

TABLE 4.

Summary of clinical evidence for the use of tetracyclines to treat slowly growing mycobacteria

Species Tetracycline antibiotic Studies (n)/patients (n)# Efficacy outcomes Safety outcomes Level/quality of evidence
Mycobacterium avium complex MIN [95, 96] 2/27
  • Approximately 64% of patients had negative sputum conversion when treated with regimens containing MIN [95]

  • Approximately 68% of patients experienced at least one AE [95]

3a; low
Mycobacterium marinum MIN [97, 100–102, 105–109] 9/89
  • Clinical improvement was observed in >70% of patients in the majority of studies [100–102, 105–108]

  • Efficacy was lower with MIN compared to comparator regimens [102]

  • Escalation of therapy due to lack of clinical effectiveness required in some patients [97]

  • Often utilised for treatment of skin and soft tissue infections rather than deeper infections [106]

  • Incidence of side-effects was reported as low [100]; although adverse reactions to MIN were reported [102]

  • Resistance noted for some isolates [109]

3b; moderate
DOX [97–99, 102, 106, 109] 6/45
  • Clinical efficacy varied across studies [98, 99, 106, 109]

  • Often utilised for treatment of skin and soft tissue infections rather than deeper infections [106]

  • Resistance to DOX observed [97, 99, 109]

  • Some studies demonstrated high rates of treatment discontinuation due to lack of efficacy/AEs [97, 98]

3b; low

The grading systems used for the level and quality of evidence are outlined in the supplementary material. AE: adverse event; DOX: doxycycline; MIN: minocycline. #: The total number of patients in the studies who were treated with the tetracycline specified. : A single study included 31 patients treated with clarithromycin combinations, of which five included MIN [96]. Efficacy data for the subset of patients receiving MIN-containing regimens was not reported.

Discussion

There is a clear unmet need for treatment options that are clinically effective and well-tolerated for NTM disease. This need is driven by several factors, including the increasing incidence and prevalence of NTM pulmonary disease, intrinsic resistance of NTM to most conventionally utilised antimicrobials [109, 111], and the high morbidity and mortality associated with disease [112–114]. Evidence collated in this review suggests that whilst tigecycline, omadacycline and eravacycline demonstrate potential as treatment options for NTM, doxycycline and minocycline are limited by high levels of resistance.

Doxycycline and minocycline have poor in vitro activity against most RGM, including M. abscessus [17, 18]. The mechanisms of resistance in M. abscessus are through a tetracycline-degrading flavin monooxygenase, MAB_1496c (also known as a “destructase”), which efficiently degrades older tetracyclines [19]. While doxycycline and/or minocycline were recommended as treatment options for M. abscessus in past NTM guidelines [12], the confirmation of resistance [19] and a lack of clinical efficacy [79–82] support their more recent omission [3]. In contrast, tigecycline has more potent in vitro activity against RGM such as M. abscessus [46]. Not only is tigecycline a poor substrate of MAB_1496c, it also does not induce its expression [19, 45], providing supportive evidence for its potent in vitro activity. Eravacycline and omadacycline also demonstrate in vitro activity against tetracycline-resistant M. abscessus isolates, suggesting they are not substrates of MAB_1496c. Additionally, the intracellular activity observed with tigecycline and omadacycline is encouraging [42, 48, 49], as the limited intracellular penetration of many of the recommended antibiotics likely contributes to poor treatment outcomes in NTM pulmonary disease [115].

Studies demonstrate tigecycline may have a positive impact on microbiological and clinical outcomes in those patients who are able to tolerate prolonged treatment courses. However, treatment modification or discontinuation is common in patients receiving tigecycline, owing mainly to gastrointestinal side effects [88]. Due to the often-lengthy courses of treatment in NTM disease it is important that treatments are well tolerated. Treatment regimens consisting of oral or inhaled antibiotics also help facilitate outpatient treatment and avoid complications associated with prolonged i.v. administration. Therefore, the i.v. route of administration and high frequency of treatment-limiting AEs with tigecycline are important drawbacks that should be factored into clinical decision making. The available data suggest better tolerability with IV and oral omadacycline compared to i.v. tigecycline, with treatment-altering AEs of ∼15% for oral omadacycline versus ∼50% with tigecycline [47, 89, 90]. Although better tolerated, to ensure adequate absorption of oral omadacycline patients must fast for 4 h before dosing. No food or drink (except water) should be consumed for 2 h post-oral dosing [116, 117]. Inhaled administration of tigecycline is also under investigation as a method to prevent systemic toxicity but retain efficacy [42, 52].

There currently remains limited data for omadacycline and eravacycline. In vitro susceptibility [25, 27, 29–31] and synergy studies [38] are available for eravacycline; however, real-world data from a single case series reported hypofibrinogenaemia in patients treated with eravacycline [67]. Omadacycline demonstrates similar activity to tigecycline against M. abscessus across multiple nonclinical studies [24–26, 28, 41, 44] and efficacy in animal models, both as monotherapy and in combination with other antimicrobials [24, 32, 51]. Clinical experience using omadacycline in the treatment of M. abscessus is limited but encouraging, with high rates of treatment response in two published retrospective studies [47, 90]. Omadacycline also has the advantage of oral administration. Evidence from this systematic review suggests that, out of all the tetracyclines, tigecycline and omadacycline may best contribute to the efficacy of combination regimens used to treat RGM infections.

Clinical experience in the treatment of SGM with tetracyclines, particularly MAC, is limited to a small number of studies, possibly due to the poor in vitro activity of tetracyclines with standard microbroth dilution methodology [62, 118]. More recent HFM studies, which can overcome the issue of instability by supplying fresh drug, demonstrate that minocycline, tigecycline, and omadacycline all have potent activity against MAC and M. kansasii, indicating that further evaluation is warranted [54, 60, 64]. The exception has been for M. marinum, where there is consensus that doxycycline or minocycline monotherapy can be used to treat nonsevere cases of skin disease, although multidrug regimens may be needed in more severe disease [97].

Strengths and limitations

This review sought to assess the evidence for tetracyclines in the treatment of NTM disease. Inclusive search terms were used to capture all potentially relevant data, which is evidenced by the large number of studies retrieved. Article screening was performed using both automated and manual validation to limit bias. However, there are some limitations to our methodology including how data are indexed in PubMed/WoS, which may have limited the data that were captured. Data collected during this systematic review were of a low level of evidence due to a lack of randomised controlled trials (RCTs) and the small patient numbers in the available studies, which is not unexpected given that NTM is an orphan disease. Applying findings from non-RCTs to clinical practice is challenging, especially given the inherent variability in data collecting and reporting. There is inherent variability in NTM species, study designs, outcomes reported, patient populations and therapeutic regimens (e.g. combination versus monotherapy), which makes it difficult to compare between studies and apply findings to clinical practice. Although this systematic review categorises disease as pulmonary or extrapulmonary, there remains considerable variability between different studies evaluating the same overarching disease types. Reporting of data was also a limiting factor which could influence the findings. Studies differed in how data, specifically efficacy outcomes, were reported making it difficult to compare between studies. Furthermore, some studies reported on multiple NTM species and in others the causative species could not be identified. As a result, species-specific data was not available for all endpoints, thus limiting the data that can be reported. Additionally, several studies utilised combination regimens for the treatment of NTM infections. Older tetracyclines such as doxycycline were often used alongside other antibiotics making it difficult to attribute efficacy and safety outcomes to a particular antibiotic.

Conclusions

New and effective antimicrobial treatments for NTM disease are urgently needed. Repurposed antibiotics such as tetracyclines have the potential to improve NTM treatment. Although tetracyclines have not been evaluated in RCTs for the treatment of NTM disease, this review identifies numerous observational and retrospective studies, as well as case series, describing the use of tetracyclines in NTM disease. Evidence suggests that when used in combination therapy for the treatment of NTM disease, inclusion of a tetracycline with in vitro activity against the causative pathogen can contribute to the efficacy of the regimen. Further, tetracyclines have also been used successfully as monotherapy in the treatment of nonsevere skin infections caused by M. marinum and certain RGM species.

Treatment outcomes for M. abscessus pulmonary disease remain poor despite guideline-based recommendations. Multiple observational studies have reported on treatment outcomes of combination regimens that have included a tetracycline in M. abscessus pulmonary disease; however, high rates of resistance to doxycycline and minocycline may limit their clinical usefulness. In contrast to older tetracyclines, tigecycline and omadacycline retain potent in vitro activity against M. abscessus and have been associated with positive clinical outcomes in the treatment of M. abscessus disease. However, the high rate of AEs associated with tigecycline may limit its clinical utility.

Points for clinical practice

The incidence and prevalence of NTM disease are increasing globally and there is a need for effective and well-tolerated treatment options. Although tetracyclines have not been evaluated in RCTs for the treatment of NTM disease, evidence from observational, retrospective and case studies demonstrate the potential of tetracyclines to improve NTM treatment. While some tetracyclines have been associated with high rates of resistance (i.e. doxycycline and minocycline) that may limit their clinical usefulness, newer tetracyclines (i.e. tigecycline and omadacycline) retain potent in vitro activity and have been associated with positive clinical outcomes. The available evidence, combined with the limitations of intravenous tigecycline, supports further clinical studies to evaluate omadacycline as a treatment for NTM disease.

Acknowledgements

Medical writing assistance was provided by Meridian HealthComms, part of Bioscript Group Ltd, Macclesfield, UK, funded by Paratek Pharmaceuticals in accordance with Good Publication Practice (GPP 2022). Paratek Pharmaceuticals, Inc. were involved in initial discussions with authors regarding the scope and aims of the review, screening of searches and reviewed the manuscript at key stages.

Footnotes

Provenance: Submitted article, peer reviewed.

The systematic review protocol was registered with PROSPERO (https://www.crd.york.ac.uk/prospero/) with identifier: CRD42024540059.

Author contributions: All authors contributed to the study concept and design, data analysis and interpretation, writing of the manuscript, review and revision of the manuscript, and final approval of the manuscript to be published. All authors agree to be accountable for all aspects of the work.

Conflict of interest: C.L. Daley has received research grants/contracts from AN2 Therapeutics, Bugworks, Insmed, Juvabis, Paratek and Renovion. He has served on advisory boards and as a consultant to AN2 Therapeutics, Cepheid, Galapagos, Genentech, GSK, Hyfe, Insmed, Lilly, MannKind, Matinas, Nob Hill, Otsuka, Paratek, Pfizer, and Spero. P.A. Flume has received research grants and/or consulting honoraria from Insmed, AN2 Therapeutics, Spero, Renovion, and Paratek. J. van Ingen has served on advisory boards for AN2 Therapeutics, Insmed, MannKind, Paratek, Pfizer and Spero. He is inventor on a Radboudumc-held patent on inhaled tigecycline for NTM disease treatment. R. Khare has received funding for laboratory contract research from Insmed, Spero Therapeutics, RedHill Biopharma, AN2 Therapeutics, Paratek and MannKind. C.M. Mingora reports grants from Cystic Fibrosis Foundation, and payment or honoraria for lectures, presentations, manuscript writing or educational events from The France Foundation. M.H. Nguyen has no competing interests to declare. K.L. Winthrop has received research grants and/or consulting honoraria from Insmed, AN2 Therapeutics, Spero, Renovion, and Paratek. B.S. Zha reports receiving consultancy fees from Genentech, and support as a site investigator for Insmed.

Support statement: Supported by Paratek Pharmaceuticals. Funding information for this article has been deposited with the Open Funder Registry.

Supplementary material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material

DOI: 10.1183/16000617.0038-2025.Supp1

ERR-0038-2025.SUPPLEMENT

References

  • 1.To K, Cao R, Yegiazaryan A, et al. General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med 2020; 9: 2541. doi: 10.3390/jcm9082541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pennington KM, Vu A, Challener D, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis 2021; 24: 100244. doi: 10.1016/j.jctube.2021.100244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56: 2000535. doi: 10.1183/13993003.00535-2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.US Food and Drug Administration . ARIKAYCE (amikacin liposome inhalation suspension), for oral inhalation use. Prescribing information. Date last updated: February 2023. Date last accessed: February 2024. www.accessdata.fda.gov/drugsatfda_docs/label/2023/207356s012lbl.pdf
  • 5.European Medicines Agency . ARIKAYCE liposomal 590 mg nebuliser dispersion SmPC. Date last updated: 2023. Date last accessed: May 2025. www.ema.europa.eu/en/documents/product-information/arikayce-liposomal-product-information_en.pdf
  • 6.ARIKAYCE . ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Kusuri-no-Shiori. Date last updated: 2022. Date last accessed: May 2025. https://arikayce.jp/data/PI.pdf
  • 7.US Food and Drug Administration . BIAXIN Filmtab (clarithromycin tablets, USP), BIAXIN XL Filmtab (clarithromycin extended-release tablets), BIAXIN Granules (clarithromycin for oral suspension, USP). Prescribing Information. Date last accessed: May 2025. www.accessdata.fda.gov/drugsatfda_docs/label/2009/050662s042,050698s024,050775s013lbl.pdf
  • 8.US Food and Drug Administration . ZITHROMAX (azithromycin) 600 mg tablets, for oral use. ZITHROMAX (azithromycin) for oral suspension. Prescribing information. Date last updated: 2021. Date last accessed: May 2025. www.accessdata.fda.gov/drugsatfda_docs/label/2021/050730s043,050693s034lbl.pdf
  • 9.Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc 2014; 11: 9–16. doi: 10.1513/AnnalsATS.201304-085OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.van Ingen J, Wagner D, Gallagher J, et al. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J 2017; 49: 1601855. doi: 10.1183/13993003.01855-2016 [DOI] [PubMed] [Google Scholar]
  • 11.Flume PA, Griffith DE, Chalmers JD, et al. Development of drugs for nontuberculous mycobacterial disease: clinicians’ interpretation of a US Food and Drug Administration Workshop. Chest 2021; 159: 537–543. doi: 10.1016/j.chest.2020.08.2055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416. doi: 10.1164/rccm.200604-571ST [DOI] [PubMed] [Google Scholar]
  • 13.Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71: Suppl. 1, i1–22. doi: 10.1136/thoraxjnl-2015-207360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72: Suppl. 2, ii1–ii64. doi: 10.1136/thoraxjnl-2017-210927 [DOI] [PubMed] [Google Scholar]
  • 15.Lange C, Böttger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis 2022; 22: e178–e190. doi: 10.1016/S1473-3099(21)00586-7 [DOI] [PubMed] [Google Scholar]
  • 16.Hurst-Hess K, Rudra P, Ghosh P. Mycobacterium abscessus WhiB7 regulates a species-specific repertoire of genes to confer extreme antibiotic resistance. Antimicrob Agents Chemother 2017; 61: e01347-17. doi: 10.1128/AAC.01347-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cho EH, Huh HJ, Song DJ, et al. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagn Microbiol Infect Dis 2019; 93: 107–111. doi: 10.1016/j.diagmicrobio.2018.08.008 [DOI] [PubMed] [Google Scholar]
  • 18.Hunkins JJ, de-Moura VC, Eddy JJ, et al. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis 2023; 105: 115882. doi: 10.1016/j.diagmicrobio.2022.115882 [DOI] [PubMed] [Google Scholar]
  • 19.Rudra P, Hurst-Hess K, Lappierre P, et al. High levels of intrinsic tetracycline resistance in Mycobacterium abscessus are conferred by a tetracycline-modifying monooxygenase. Antimicrob Agents Chemother 2018; 62: e00119-18. doi: 10.1128/AAC.00119-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics 2021; 13: 2085. doi: 10.3390/pharmaceutics13122085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wallace RJJ, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164–3167. doi: 10.1128/AAC.46.10.3164-3167.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Global Health 2024; 25: 101484. doi: 10.1016/j.cegh.2023.101484 [DOI] [Google Scholar]
  • 23.Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 2011; 128: 305–310. doi: 10.1097/PRS.0b013e318219c171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shoen C, Benaroch D, Sklaney M, et al. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother 2019; 63: e02522-18. doi: 10.1128/AAC.02522-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Brown-Elliott BA, Wallace RJ, Jr. In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother 2021; 65: e01947-20. doi: 10.1128/AAC.01947-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chew KL, Octavia S, Go J, et al. In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens. J Antimicrob Chemother 2021; 76: 973–978. doi: 10.1093/jac/dkaa520 [DOI] [PubMed] [Google Scholar]
  • 27.Brown-Elliott BA, Wallace RJ, Jr. In vitro susceptibility testing of eravacycline against nontuberculous mycobacteria. Antimicrob Agents Chemother 2022; 66: e0068922. doi: 10.1128/aac.00689-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kaushik A, Ammerman NC, Martins O, et al. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother 2019; 63: e00470-19. doi: 10.1128/AAC.00470-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Nicklas DA, Maggioncalda EC, Story-Roller E, et al. Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. Antimicrob Agents Chemother 2022; 66: e0170421. doi: 10.1128/AAC.01704-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhang T, Du J, Dong L, et al. In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria. Microbiol Spectr 2023; 11: e0323822. doi: 10.1128/spectrum.03238-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Li A, He S, Li J, et al. Omadacycline, eravacycline, and tigecycline express anti-Mycobacterium abscessus activity in vitro. Microbiol Spectr 2023; 11: e0071823. doi: 10.1128/spectrum.00718-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Aziz DB, Teo JWP, Dartois V, et al. Teicoplanin–tigecycline combination shows synergy against Mycobacterium abscessus. Front Microbiol 2018; 9: 932. doi: 10.3389/fmicb.2018.00932 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bich Hanh BT, Quang NT, Park Y, et al. Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus. Front Pharmacol 2021; 12: 790767. doi: 10.3389/fphar.2021.790767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cheng A, Tsai YT, Chang SY, et al. In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the Mycobacterium abscessus complex. Antimicrob Agents Chemother 2019; 63: e02234-18. doi: 10.1128/AAC.02234-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chew KL, Octavia S, Yeoh SF, et al. In vitro synergy testing of eravacycline in combination with clarithromycin and rifabutin against Mycobacterium abscessus complex. Microbiol Spectr 2021; 9: e0004521. doi: 10.1128/Spectrum.00045-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fujiwara K, Aono A, Asami T, et al. In vitro synergistic effects of omadacycline with other antimicrobial agents against Mycobacterium abscessus. Antimicrob Agents Chemother 2023; 67: e0157922. doi: 10.1128/aac.01579-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Huang CW, Chen JH, Hu ST, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013; 41: 218–223. doi: 10.1016/j.ijantimicag.2012.10.021 [DOI] [PubMed] [Google Scholar]
  • 38.Pryjma M, Burian J, Thompson CJ. Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination. Antimicrob Agents Chemother 2018; 62: e00283-18. doi: 10.1128/AAC.00283-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Singh S, Bouzinbi N, Chaturvedi V, et al. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 2014; 20: O1124–O1127. doi: 10.1111/1469-0691.12780 [DOI] [PubMed] [Google Scholar]
  • 40.Ruth MM, Sangen JJN, Pennings LJ, et al. Minocycline has no clear role in the treatment of Mycobacterium abscessus disease. Antimicrob Agents Chemother 2018; 62: e01208-18. doi: 10.1128/AAC.01208-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bax HI, de Vogel CP, Mouton JW, et al. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus. J Antimicrob Chemother 2019; 74: 2930–2933. doi: 10.1093/jac/dkz267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Pearce C, Ruth MM, Pennings LJ, et al. Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo. J Antimicrob Chemother 2020; 75: 1889–1894. doi: 10.1093/jac/dkaa110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Portell-Buj E, Bonet-Rossinyol Q, López-Gavín A, et al. Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay. J Antibiot (Tokyo) 2021; 74: 285–290. doi: 10.1038/s41429-020-00392-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Gumbo T, Cirrincione K, Srivastava S. Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill. J Antimicrob Chemother 2020; 75: 1212–1217. doi: 10.1093/jac/dkz523 [DOI] [PubMed] [Google Scholar]
  • 45.Schildkraut JA, Coolen JPM, Burbaud S, et al. RNA sequencing elucidates drug-specific mechanisms of antibiotic tolerance and resistance in Mycobacterium abscessus. Antimicrob Agents Chemother 2022; 66: e0150921. doi: 10.1128/AAC.01509-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ferro BE, Srivastava S, Deshpande D, et al. Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother 2016; 60: 2895–2900. doi: 10.1128/AAC.03112-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Singh S, Wang JY, Heysell SK, et al. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease. Int J Antimicrob Agents 2023; 62: 106847. doi: 10.1016/j.ijantimicag.2023.106847 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Molina-Torres CA, Tamez-Peña L, Castro-Garza J, et al. Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model. J Microbiol Methods 2018; 148: 29–32. doi: 10.1016/j.mimet.2018.03.020 [DOI] [PubMed] [Google Scholar]
  • 49.Jahanbakhsh S, Howland J, Ndayishimiye Uwineza MO, et al. Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages. JAC Antimicrob Resist 2023; 5: dlad104. doi: 10.1093/jacamr/dlad104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lerat I, Cambau E, Roth Dit Bettoni R, et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis 2014; 209: 905–912. doi: 10.1093/infdis/jit614 [DOI] [PubMed] [Google Scholar]
  • 51.Rimal B, Nicklas DA, Panthi CM, et al. Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease. mSphere 2023; 8: e0066522. doi: 10.1128/msphere.00665-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Maloney SE, Alshiraihi IM, Singh A, et al. Spray dried tigecycline dry powder aerosols for the treatment of nontuberculous mycobacterial pulmonary infections. Tuberculosis (Edinb) 2023; 139: 102306. doi: 10.1016/j.tube.2023.102306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, et al. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. J Antimicrob Chemother 2023; 78: 2849–2858. doi: 10.1093/jac/dkad317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ruth MM, Magombedze G, Gumbo T, et al. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. J Antimicrob Chemother 2019; 74: 1952–1961. doi: 10.1093/jac/dkz143 [DOI] [PubMed] [Google Scholar]
  • 55.Bax HI, Bakker-Woudenberg IA, Ten KMT, et al. Tigecycline potentiates clarithromycin activity against Mycobacterium avium in vitro. Antimicrob Agents Chemother 2016; 60: 2577–2579. doi: 10.1128/AAC.02864-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Deshpande D, Srivastava S, Gumbo T, et al. Tiger roars: tigecycline pharmacokinetics/pharmacodynamic (PK/PD) based treatment of pulmonary Mycobacterium avium complex (MAC) disease. Am J Respir Crit Care Med 2020; 201: A4349. doi: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4349 [DOI] [Google Scholar]
  • 57.Singh S, Boorgula GD, Aryal S, et al. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far. J Antimicrob Chemother 2024; 79: 96–99. doi: 10.1093/jac/dkad352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Chapagain M, Gumbo T, Heysell SK, et al. Comparison of a novel regimen of rifapentine, tedizolid, and minocycline with standard regimens for treatment of pulmonary Mycobacterium kansasii. Antimicrob Agents Chemother 2020; 64: e00810-20. doi: 10.1128/AAC.00810-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Raaijmakers J, Ruth MM, Schildkraut JA, et al. Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system. Int J Antimicrob Agents 2024; 65: 107423. doi: 10.1016/j.ijantimicag.2024.107423 [DOI] [PubMed] [Google Scholar]
  • 60.Singh S, Gumbo T, Boorgula GD, et al. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model and potential combination regimen for short course treatment of Mycobacterium kansasii pulmonary disease. Antimicrob Agents Chemother 2022; 66: e0068722. doi: 10.1128/aac.00687-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Shankar P, Singh S, Boorgula GD, et al. Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria. Tuberculosis (Edinb) 2022; 137: 102269. doi: 10.1016/j.tube.2022.102269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hope R, Warner M, Mushtaq S, et al. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 2005; 56: 1042–1046. doi: 10.1093/jac/dki386 [DOI] [PubMed] [Google Scholar]
  • 63.van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15: 149–161. doi: 10.1016/j.drup.2012.04.001 [DOI] [PubMed] [Google Scholar]
  • 64.Chapagain M, Pasipanodya JG, Athale S, et al. Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses. J Antimicrob Chemother 2022; 77: 1694–1705. doi: 10.1093/jac/dkac068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Deshpande D, Srivastava S, Meek C, et al. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010; 54: 1728–1733. doi: 10.1128/AAC.01355-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Siddiqa A, Khan S, Rodriguez GD, et al. Omadacycline for the treatment of Mycobacterium abscessus infections: case series and review of the literature. IDCases 2023; 31: e01703. doi: 10.1016/j.idcr.2023.e01703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Rausch E, Vemuri K, Anderman TM, et al. Eravacycline associated hypofibrinogenemia: a case series of transplant patients with Mycobacterium Abscessus infections and review of literature. Open Forum Infect Dis 2022; 9: ofac591. doi: 10.1093/ofid/ofac591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Duah M, Beshay M. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series. Int J Infect Dis 2022; 122: 953–956. doi: 10.1016/j.ijid.2022.06.061 [DOI] [PubMed] [Google Scholar]
  • 69.Leow TYS, Bekkers S, Janssen AM, et al. Quality of life in children receiving treatment for Mycobacterium abscessus otomastoiditis. Clin Otolaryngol 2022; 47: 529–535. doi: 10.1111/coa.13931 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Baker AW, Maziarz EK, Lewis SS, et al. Invasive Mycobacterium abscessus complex infection after cardiac surgery: epidemiology, management, and clinical outcomes. Clin Infect Dis 2021; 72: 1232–1240. doi: 10.1093/cid/ciaa215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Pearson JC, Dionne B, Richterman A, et al. Omadacycline for the treatment of Mycobacterium abscessus disease: a case series. Open Forum Infect Dis 2020; 7: ofaa415. doi: 10.1093/ofid/ofaa415 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.van Wijk F, Waterval J, van Aerde K, et al. Successful systemic and topical treatment of Mycobacterium abscessus otomastoiditis. Antimicrob Agents Chemother 2019; 64: e01203-19. doi: 10.1128/AAC.01203-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Rodríguez-Cerdeira C, Hernández-Castro R, Sánchez-Cárdenas CD, et al. Atypical mycobacteriosis due to Mycobacterium abscessus subsp. massiliense: our experience. Pathogens 2022; 11: 1399. doi: 10.3390/pathogens11121399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Sánchez-Vargas FM, Gaviria-López AF, Nanjappa S, et al. Breast wound infections with rapidly growing mycobacteria after cancer surgery. Infect Dis Clin Pract 2017; 25: 126. doi: 10.1097/IPC.0000000000000407 [DOI] [Google Scholar]
  • 75.Regnier S, Cambau E, Meningaud JP, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009; 49: 1358–1364. doi: 10.1086/606050 [DOI] [PubMed] [Google Scholar]
  • 76.Threadgill R, Mohamedy I, Lininger N, et al. Clinical experience with tigecycline-containing regimens for treatment of Mycobacterium abscessus complex and Mycobacterium chelonae infections. Chest 2020; 158: A319. doi: 10.1016/j.chest.2020.08.316 [DOI] [Google Scholar]
  • 77.Ip FK, Chow SP. Mycobacterium fortuitum infections of the hand. Report of five cases. J Hand Surg Br 1992; 17: 675–677. doi: 10.1016/0266-7681(92)90199-C [DOI] [PubMed] [Google Scholar]
  • 78.Dalovisio JR, Pankey GA, Wallace RJ, et al. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 1981; 3: 1068–1074. doi: 10.1093/clinids/3.5.1068 [DOI] [PubMed] [Google Scholar]
  • 79.Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 2017; 64: 309–316. doi: 10.1093/cid/ciw724 [DOI] [PubMed] [Google Scholar]
  • 80.Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405–410. doi: 10.1164/rccm.201003-0395OC [DOI] [PubMed] [Google Scholar]
  • 81.Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896–902. doi: 10.1164/rccm.200905-0704OC [DOI] [PubMed] [Google Scholar]
  • 82.Chen J, Zhao L, Mao Y, et al. Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease. Front Microbiol 2019; 10: 1977. doi: 10.3389/fmicb.2019.01977 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Im Y, Kim SY, Kim DH, et al. Outcomes of intermittent multidrug iv therapy for refractory Mycobacterium abscessus pulmonary disease. Chest 2023; 165: 288–302. doi: 10.1016/j.chest.2023.08.025 [DOI] [PubMed] [Google Scholar]
  • 84.Kim SR, Jang M, Kim SY, et al. Outcomes of short-term tigecycline-containing regimens for Mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother 2022; 66: e0077422. doi: 10.1128/aac.00774-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Yang JH, Wang PH, Pan SW, et al. Treatment outcome in patients with Mycobacterium abscessus complex lung disease: the impact of tigecycline and amikacin. Antibiotics (Basel) 2022; 11: 571. doi: 10.3390/antibiotics11050571 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Kwon YS, Levin A, Kasperbauer SH, et al. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir Med 2019; 158: 89–91. doi: 10.1016/j.rmed.2019.10.006 [DOI] [PubMed] [Google Scholar]
  • 87.Czaja CA, Levin AR, Cox CW, et al. Improvement in quality of life after therapy for Mycobacterium abscessus group lung infection. a prospective cohort study. Ann Am Thorac Soc 2016; 13: 40–48. doi: 10.1513/AnnalsATS.201508-529OC [DOI] [PubMed] [Google Scholar]
  • 88.Wallace RJJ, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014; 69: 1945–1953. doi: 10.1093/jac/dku062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Mingora CM, Bullington W, Faasuamalie PE, et al. Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections. Open Forum Infect Dis 2023; 10: ofad335. doi: 10.1093/ofid/ofad335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.El Ghali A, Morrisette T, Alosaimy S, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother 2023; 67: e0082423. doi: 10.1128/aac.00824-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Wallace RJJ, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152: 500–514. doi: 10.1093/infdis/152.3.500 [DOI] [PubMed] [Google Scholar]
  • 92.Brown-Elliott BA, Wallace RJ, Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716–746. doi: 10.1128/CMR.15.4.716-746.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. Int J Syst Bacteriol 1992; 42: 240–245. doi: 10.1099/00207713-42-2-240 [DOI] [PubMed] [Google Scholar]
  • 94.Winthrop KL, Albridge K, South D, et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38: 38–44. doi: 10.1086/380459 [DOI] [PubMed] [Google Scholar]
  • 95.Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis 1998; 2: 462–470. [PubMed] [Google Scholar]
  • 96.Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin study group of France. Chest 1995; 107: 1035–1040. doi: 10.1378/chest.107.4.1035 [DOI] [PubMed] [Google Scholar]
  • 97.Hendrikx L, van Hees CLM, de Steenwinkel JEM, et al. Treatment and outcome of culture-confirmed Mycobacterium marinum disease. Open Forum Infect Dis 2022; 9: ofac077. doi: 10.1093/ofid/ofac077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Strobel K, Sickenberger C, Schoen C, et al. Diagnosis and therapy of Mycobacterium marinum: a single-center 21-year retrospective analysis. J Dtsch Dermatol Ges 2022; 20: 1211–1218. doi: 10.1111/ddg.14847 [DOI] [PubMed] [Google Scholar]
  • 99.Wu TS, Chiu CH, Yang CH, et al. Fish tank granuloma caused by Mycobacterium marinum. PLoS One 2012; 7: e41296. doi: 10.1371/journal.pone.0041296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Casal M, Casal MM. Multicenter study of incidence of Mycobacterium marinum in humans in Spain. Int J Tuberc Lung Dis 2001; 5: 197–199. [PubMed] [Google Scholar]
  • 101.Ang P, Rattana-Apiromyakij N, Goh CL. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000; 39: 343–347. doi: 10.1046/j.1365-4362.2000.00916.x [DOI] [PubMed] [Google Scholar]
  • 102.Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med 1994; 154: 1359–1364. doi: 10.1001/archinte.1994.00420120079009 [DOI] [PubMed] [Google Scholar]
  • 103.Iredell J, Whitby M, Blacklock Z. Mycobacterium marinum infection: epidemiology and presentation in Queensland 1971–1990. Med J Aust 1992; 157: 596–598. doi: 10.5694/j.1326-5377.1992.tb137399.x [DOI] [PubMed] [Google Scholar]
  • 104.Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Wayne, Clinical and Laboratory Standards Institute, 2011. [PubMed] [Google Scholar]
  • 105.Bonamonte D, De VD, Vestita M, et al. Aquarium-borne Mycobacterium marinum skin infection. Report of 15 cases and review of the literature. Eur J Dermatol 2013; 23: 510–516. doi: 10.1684/ejd.2013.2103 [DOI] [PubMed] [Google Scholar]
  • 106.Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162: 1746–1752. doi: 10.1001/archinte.162.15.1746 [DOI] [PubMed] [Google Scholar]
  • 107.Ryan JM, Bryant GD. Fish tank granuloma–a frequently misdiagnosed infection of the upper limb. J Accid Emerg Med 1997; 14: 398–400. doi: 10.1136/emj.14.6.398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Hurst LC, Amadio PC, Badalamente MA, et al. Mycobacterium marinum infections of the hand. J Hand Surg Am 1987; 12: 428–435. doi: 10.1016/S0363-5023(87)80018-7 [DOI] [PubMed] [Google Scholar]
  • 109.Donta ST, Smith PW, Levitz RE, et al. Therapy of Mycobacterium marinum infections. Use of tetracyclines vs rifampin. Arch Intern Med 1986; 146: 902–904. doi: 10.1001/archinte.1986.00360170104017 [DOI] [PubMed] [Google Scholar]
  • 110.Izumi AK, Hanke CW, Higaki M. Mycobacterium marinum infections treated with tetracycline. Arch Dermatol 1977; 113: 1067–1068. doi: 10.1001/archderm.1977.01640080069009 [DOI] [PubMed] [Google Scholar]
  • 111.Saxena S, Spaink HP, Forn-Cuni G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel) 2021; 10: 96. doi: 10.3390/biology10020096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Wang PH, Pan SW, Wang SM, et al. The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease. Front Microbiol 2022; 13: 909274. doi: 10.3389/fmicb.2022.909274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Kim HJ, Kwak N, Hong H, et al. BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease. Am J Respir Crit Care Med 2021; 203: 230–236. doi: 10.1164/rccm.202004-1418OC [DOI] [PubMed] [Google Scholar]
  • 114.Gopalaswamy R, Shanmugam S, Mondal R, et al. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci 2020; 27: 74. doi: 10.1186/s12929-020-00667-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Sousa S, Bandeira M, Carvalho PA, et al. Nontuberculous mycobacteria pathogenesis and biofilm assembly. Int J Mycobacteriol 2015; 4: 36–43. doi: 10.1016/j.ijmyco.2014.11.065 [DOI] [PubMed] [Google Scholar]
  • 116.US Food and Drug Administration . NUZYRA (omadacycline), for injection, for intravenous use NUZYRA (omadacycline) tablets, for oral use. Prescribing information. Date last updated: 2018. Date last accessed: May 2025. www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf
  • 117.Gotfried MH, Horn K, Garrity-Ryan L, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother 2017; 61: e01135-17. doi: 10.1128/AAC.01135-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Bradford PA, Petersen PJ, Young M, et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49: 3903–3909. doi: 10.1128/AAC.49.9.3903-3909.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Serio AW, Deck DH, Wright K, et al. Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable. Antimicrob Agents Chemother 2024; 68: e0063824. doi: 10.1128/aac.00638-24 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material

DOI: 10.1183/16000617.0038-2025.Supp1

ERR-0038-2025.SUPPLEMENT


Articles from European Respiratory Review are provided here courtesy of European Respiratory Society

RESOURCES